Medtronic Plc. announced the launch of a new hybrid closed-loop system for North America & Europe artificial pancreas systems market
The
increasing incidence of type 1 diabetes is significantly fueling the growth of
the North America & Europe artificial pancreas systems market. For
instance, according to the Centers for Disease Control and Prevention (CDC), in
the U.S., around 40,000 people are diagnosed with Type 1 diabetes, annually,
and by 2050, 5 million people are expected to be diagnosed with the disease, in
the country. Moreover, Germany had the highest prevalence of diabetes in Europe
among their adult population with 15.3 percent living with diabetes in 2019,
Portugal followed with the second-highest share at 14.2 percent. Furthermore,
the growing adoption of high-end systems in diabetes management is further
projected to foster the growth of the North America & Europe artificial
pancreas systems market.
North
America region is expected to hold a dominant position in North
America & Europe artificial pancreas systems market and this is attributed to the
presence of a well-established healthcare sector and high prevalence of
diabetes disease in the region.
1. In June 2017, Medtronic Plc.
announced the launch of a new hybrid closed-loop system (near-artificial
pancreas) for people with type 1 diabetes in the U.S
2. In January 2020, Medtech Company
Beta Bionics has received the FDA Breakthrough Device designation for its
automated bionic pancreas – the iLet Bionic Pancreas System. The iLet Bionic
Pancreas System is a pocket-sized, wearable investigational medical device that
is designed to autonomously control blood-sugar levels.
3. In January 2021, Medtronic
launched The MiniMed 780G system, an advanced hybrid closed-loop insulin
delivery system aimed at simplifying the management of type 1 diabetes
The
introduction of hybrid closed-loop artificial pancreas systems is expected to
provide potential growth opportunities for players in North America and Europe
artificial pancreas systems market. For instance, in December 2019, Tandem
Diabetes Care, Inc. received the U.S. FDA clearance for its t: slim X2 insulin pump
with Control-IQ technology, an advanced hybrid-closed loop feature.
There
are many different types of artificial pancreas systems available in the market
today, but the most popular among them is the mechanical type which basically
is mechanical like pumps, which is used for controlling the secretion of human
insulin into the bloodstream. The process of having an artificial pancreas
involves the introduction of an infusion pump or some type of electronic device
that will allow the insulin, into the body. There are many benefits that an
artificial pancreas system can offer. The most common positive effect of an
artificial pancreas is the prevention of insulin shock.
Comments
Post a Comment